Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Strong near-term momentum with a fresh high on 2026-07-22, major Q1 2026 turnaround to high margins and strong cash flow, YUTREPIA commercial traction, and S&P SmallCap 600 inclusion effective 2026-06-22.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Profit turnaround ⢠Strong liquidity ⢠High leverage LQDA has sharply improved, turning profitable with strong margins, solid liquidity, and positive free cash flow, but still faces meaningful leverage, a long loss history, and a rich valuation.
Price Behavior
Key Price Behavior Insights: ⢠Higher lows ⢠Rebound strength ⢠Breakout test Support Level: $84 to $86 Resistance Level: Around $90 LQDA remains in a strong short-term uptrend, but after a rapid move into $90 resistance it may need to hold the mid-$80s to confirm the breakout.
Sentiment & News
Key News Insights: ⢠Yutrepia traction ⢠Profitability improving ⢠Earnings catalyst Liquidia's Yutrepia launch is gaining traction in PAH, supporting growth, profitability and a self-funded pipeline, but the stock remains volatile ahead of Q2 earnings and in a competitive market.
AI Summary
LQDA has shifted from a speculative pre-commercial biotech to a profitable, cash-generating launch story, so the investment case now hinges on sustaining Yutrepia momentum and proving pipeline follow-through, while the main near-term downside is a rich valuation compounded by patent litigation and any slowdown in prescription growth.
Description
Liquidia Corporation is a U.S.-based biopharmaceutical company that develops, manufactures and commercializes therapies to address unmet clinical needs. Its portfolio includes an inhaled dry powder formulation of treprostinil for pulmonary arterial hypertension and it also markets generic treprostinil injection domestically. The company was founded in 2004 and is headquartered in Morrisville, North Carolina.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 22 | Jul 29 | LQDA | Liquidia Corporation | Strong near-term momentum with a fresh high on 2026-07-22, major Q1 2026 turnaround to high margins and strong cash flow, YUTREPIA commercial traction, and S&P SmallCap 600 inclusion effective 2026-06-22. | Closed | -0.3% |
| Jul 6 | Jul 13 | LQDA | Liquidia Corporation | Commercial and technical momentum are strong: Q1 2026 included about $130M in YUTREPIA net sales, over 4,500 unique prescriptions, a third straight profitable quarter, and positive cash generation. S&P SmallCap 600 inclusion effective 2026-06-22 adds visibility, and shares are up about 30% over 21 trading days. | Closed | -10.1% |
| Jun 23 | Jun 30 | LQDA | Liquidia Corporation | Strong healthcare momentum with shares up about 24% over 21 trading days and at a new closing high, supported by Q1 2026 YUTREPIA net product sales around $130M, a third straight profitable quarter, positive free cash flow, and S&P SmallCap 600 inclusion. | Closed | +7.7% |
| Jun 16 | Jun 23 | LQDA | Liquidia Corporation | Constructive biotech momentum with a near-term index catalyst: Q1 2026 net product sales were about $130M, the company posted a third consecutive profitable quarter, and S&P SmallCap 600 inclusion is effective 2026-06-22. Shares are up about 20% over 21 trading days and remain above short-term trend. | Closed | +8.9% |
| Jun 8 | Jun 15 | LQDA | Liquidia Corporation | Commercial biotech momentum supported by strong YUTREPIA execution: latest quarter showed about $130M in net product sales, EPS beat consensus ($0.52 vs. $0.34), profitability improved for a third straight profitable quarter, and the stock is up about 50% over 21 trading days. | Closed | +12.4% |
| Jun 1 | Jun 8 | LQDA | Liquidia Corporation | Biotech/commercial momentum name with strong recent execution: YUTREPIA sales were about $130M-$133M, prescriptions exceeded 4,500, profitability reached a third straight quarter, adjusted EBITDA was positive, and free cash flow was strong. Stock is up about 56% over 21 trading days. | Closed | +8.8% |
| May 22 | May 29 | LQDA | Liquidia Corporation | Strong biotech execution and momentum: Q1 2026 showed about $130M of YUTREPIA net sales, more than 4,500 unique prescriptions, a third straight profitable quarter, and improved cash; stock is up about 66% over 21 trading days. | Closed | +1.4% |
| May 13 | May 20 | LQDA | Liquidia Corporation | Strong operating inflection and price momentum: Q1 2026 YUTREPIA net product sales were about $130M, with more than 4,500 unique prescriptions, a third straight profitable quarter, net income around $53M, adjusted EBITDA of $71M, and free cash flow near $50M. Shares are up about 41% over 21 trading days. | Closed | +7.3% |